INTS Stock Summary and Trading Ideas (Intensity Therapeutics | NASDAQ:INTS)

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics trades on the NASDAQ stock market under the symbol INTS.

As of April 9, 2025, INTS stock price declined to $1.92 with 7,489 million shares trading.

INTS has a beta of 0.68, meaning it tends to be less sensitive to market movements. INTS has a correlation of 0.03 to the broad based SPY ETF.

INTS has a market cap of $29.15 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that INTS belongs to (by Net Assets): VTI, VXF, IWC.

INTS has underperformed the market in the last year with a return of -59.9%, while SPY returned +3.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in INTS shares. However, INTS has outperformed the market in the last 3 month and 2 week periods, returning -3.0% and -5.4%, while SPY returned -9.9% and -8.0%, respectively. This indicates INTS has been having a stronger performance recently.

INTS support price is $1.83 and resistance is $2.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INTS shares will trade within this expected range on the day.